文献速递头颈外科

甲状腺叶切除术与全甲状腺切除联合同侧侧颈淋巴结清扫术治疗N1b中危甲状腺乳头状癌的比较

Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary Thyroid Carcinoma.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

这项回顾性队列研究在日本伊藤医院纳入401例中危cN1b甲状腺乳头状癌患者,比较甲状腺叶切除联合同侧侧颈清扫与全甲状腺切除联合同侧侧颈清扫的生存和复发结局;经逆概率治疗加权调整后,两组总生存、无复发生存及改良无复发生存均无显著差异。

要点

  • 中危cN1b甲状腺乳头状癌患者中,叶切除与全甲状腺切除联合侧颈清扫的预后和复发结局相当。
  • 叶切除组与全甲状腺切除组的总生存、无复发生存和改良无复发生存的风险比均未达统计学显著。
  • 这些数据可能有助于未来指南修订,并支持患者与临床医生共同决策。

核心结论

  • 在这项研究中,对于这些经过选择的中危cN1b甲状腺乳头状癌病例,全甲状腺切除与甲状腺叶切除在预后和复发方面提供了相当的结局。
  • 这些数据可能有助于未来指南修订,并支持患者与临床医生之间的共同决策。

研究设计与样本

  • 这项回顾性队列研究在日本东京伊藤医院进行,纳入2005年1月至2012年12月期间接受手术的甲状腺乳头状癌患者。
  • 排除高危甲状腺乳头状癌以及同时存在其他甲状腺癌的患者。
  • 共纳入401例患者,其中女性317例(79.1%),中位(IQR)年龄为47(36-59)岁。
  • 157例接受甲状腺叶切除联合同侧侧颈淋巴结清扫,244例接受全甲状腺切除联合同侧侧颈淋巴结清扫。
  • 中位(IQR)随访时间为13.0(11.2-15.0)年。

主要发现

  • 经IPTW调整的5年、10年和15年总生存率在叶切除组分别为98.0%(95% CI,93.9-99.3)、97.5%(95% CI,93.2-99.1)和96.8%(95% CI,92.2-98.7),在全甲状腺切除组分别为99.4%(95% CI,97.0-99.9)、97.4%(95% CI,94.4-98.8)和96.9%(95% CI,93.3-98.5)(HR,1.10;95% CI,0.35-3.47)。
  • 经IPTW调整的5年、10年和15年无复发生存率在叶切除组分别为93.8%(95% CI,88.5-96.7)、88.4%(95% CI,82.0-92.6)和84.1%(95% CI,76.8-89.3),在全甲状腺切除组分别为95.4%(95% CI,91.8-97.4)、92.9%(95% CI,88.8-95.5)和87.8%(95% CI,80.8-92.4)(HR,1.41;95% CI,0.79-2.54)。
  • 经IPTW调整的5年、10年和15年改良无复发生存率在叶切除组分别为96.7%(95% CI,92.2-98.6)、93.8%(95% CI,88.5-96.7)和88.9%(95% CI,82.4-93.1),在全甲状腺切除组分别为95.4%(95% CI,91.8-97.4)、92.9%(95% CI,88.8-95.5)和87.8%(95% CI,80.8-92.4)(HR,0.93;95% CI,0.49-1.76)。

关键数值与推荐

  • 经IPTW调整的总生存风险比(叶切除组 vs 全甲状腺切除组)为HR 1.10(95% CI,0.35-3.47)。
  • 经IPTW调整的无复发生存风险比(叶切除组 vs 全甲状腺切除组)为HR 1.41(95% CI,0.79-2.54)。
  • 经IPTW调整的改良无复发生存风险比(叶切除组 vs 全甲状腺切除组)为HR 0.93(95% CI,0.49-1.76)。

临床怎么用

  • 对于经过选择的中危cN1b甲状腺乳头状癌病例,全甲状腺切除与甲状腺叶切除在预后和复发方面提供了相当的结局。
  • 这些数据可能有助于未来指南修订,并支持患者与临床医生之间的共同决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The management of papillary thyroid carcinoma (PTC), particularly in cases with clinically apparent lateral neck lymph node metastasis (cN1b), remains an area of debate. The surgical options for PTC, including total thyroidectomy and lobectomy, have distinct impacts on patients' outcomes and quality of life. OBJECTIVE: To compare survival and recurrence outcomes between patients who underwent a lobectomy plus ipsilateral lateral neck dissection (LND) and those who underwent a total thyroidectomy plus ipsilateral LND for intermediate-risk cN1b PTC with both primary tumors and lymph node metastases in the ipsilateral neck region. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted at Ito Hospital, Tokyo, Japan. Patients who underwent surgery for PTC between January 2005 and December 2012 were included, and those with high-risk PTCs and concurrent other thyroid cancers were excluded. Data were analyzed from April to August 2024. EXPOSURES: Lobectomy plus LND vs total thyroidectomy plus LND. MAIN OUTCOMES AND MEASURES: An inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis and a Cox proportional hazards regression analysis were performed to compare the patients' overall survival, recurrence-free survival (RFS), and modified RFS (which considered the potential need for a future contralateral lobectomy). RESULTS: Of 401 included patients, 317 (79.1%) were female, and the median (IQR) age was 47 (36-59) years. A total of 157 patients underwent lobectomy plus ipsilateral LND and 244 underwent total thyroidectomy plus ipsilateral LND. The median (IQR) follow-up time was 13.0 (11.2-15.0) years. The IPTW-adjusted overall survival rates at 5, 10, and 15 years were 98.0% (95% CI, 93.9-99.3), 97.5% (95% CI, 93.2-99.1), and 96.8% (95% CI, 92.2-98.7), respectively, for the lobectomy group vs 99.4% (95% CI, 97.0-99.9), 97.4% (95% CI, 94.4-98.8), and 96.9% (95% CI, 93.3-98.5), respectively, for the total thyroidectomy group (hazard ratio [HR], 1.10; 95% CI, 0.35-3.47). The IPTW-adjusted RFS rates at 5, 10, and 15 years were 93.8% (95% CI, 88.5-96.7), 88.4% (95% CI, 82.0-92.6), and 84.1% (95% CI, 76.8-89.3), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 1.41; 95% CI, 0.79-2.54). The IPTW-adjusted modified RFS rates at 5, 10, and 15 years were 96.7% (95% CI, 92.2-98.6), 93.8% (95% CI, 88.5-96.7), and 88.9% (95% CI, 82.4-93.1), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 0.93; 95% CI, 0.49-1.76). CONCLUSIONS AND RELEVANCE: In this study, for these selected intermediate-risk cN1b PTC cases, total thyroidectomy and lobectomy provided comparable outcomes in terms of prognosis and recurrence. These data may help inform future guideline revisions and support joint decision-making between patients and their clinicians.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Saito Y, Matsuzu K, Abdelhamid Ahmed AH, et al. Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 39602155. doi:10.1001/jamaoto.2024.3860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。